Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
Gastro-intestinal Stromal Tumours
DRUG: oral masitinib
Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST), 2 months
Progression Free Survival, until disease progression
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.